In this rapid radiochemical assay for 3-hydroxy-3-methylglutaryl-coenzyme A lyase (I) activity in cell extracts, DL-3[glutaryl-3-14C]hydroxy-3-methylglutaryl-coenzyme A is used as substrate and the radiochemical product, [3-14C]acetoacetic acid, is converted to the more stable [3-14C]-3-hydroxybutyric acid in the presence of added NADH and 3-hydroxybutyrate dehydrogenase. Substrate and product are separated and quantified by thin-layer chromatography on cellulose (solvent system: butanol/water/formic acid, 77:13:10 by vol). All reagents for the assay are commercially available. No detailed column chromatography or spectrophotometry is required. Thus the assay is suited for any clinical laboratory. Using this procedure, we studied cultured fibroblasts or lymphocytes isolated from whole blood from five patients in whom the urinary organic acid profile was suggestive of deficiency of I. Three patients had less than or equal to 18% of control I activity in fibroblast or lymphocyte extracts. The other two had activity within the normal range. In one of the latter cases, urinary excretion of three of the characteristic acids disappeared with age, and 3-hydroxyisovaleric acid excretion was within normal limits. The other case presented with urinary excretion of moderate amounts of all four metabolites and the characteristic absence of urinary ketone bodies. Evidently, confirmatory enzyme studies should be undertaken, even when the profile of urinary organic acids appears definitive for this deficiency.

Download full-text PDF

Source

Publication Analysis

Top Keywords

radiochemical assay
8
cell extracts
8
thin-layer chromatography
8
urinary organic
8
urinary excretion
8
acid
5
urinary
5
3-hydroxy-3-methylglutaryl-coa lyase
4
lyase deficiency
4
deficiency detected
4

Similar Publications

Indium-111-Labeled Single-Domain Antibody for CXCR4 Imaging Using Single-Photon Emission Computed Tomography.

Bioconjug Chem

March 2025

Laboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven 3000, Belgium.

C-X-C chemokine receptor type 4 (CXCR4) is highly expressed in a range of pathologies, including cancers like multiple myeloma and non-Hodgkin lymphoma, inflammatory diseases such as rheumatoid arthritis, and viral infections like HIV. Currently, the most advanced radiotracer for CXCR4 imaging in clinics is [Ga]PentixaFor. However, its structure is prone to modifications, complicating the development of a specific CXCR4 fluorine-18-labeled tracer with good pharmacokinetic properties.

View Article and Find Full Text PDF

Development of a Radiogallium-Labeled Heterodivalent Imaging Probe Targeting Negative Charges and Integrin on the Surface of Cancer Cell Membranes.

Mol Pharm

March 2025

Laboratory of Clinical Analytical Sciences, Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan.

Radiopharmaceuticals targeting tumor-specific environments are powerful tools for cancer diagnosis and treatment. We previously demonstrated the considerable high tumor uptake of the cationic amphiphilic peptide, Ga-NOTA-KV6, in vivo. However, because this radioligand shows a relatively rapid clearance from the tumor over time, further structural optimization is necessary.

View Article and Find Full Text PDF

Combination of gut microbiota, proinflammatory cytokine, and F-FDG PET as potential indicators for predicting breast cancer recurrence.

Sci Rep

March 2025

Department of Nuclear Medicine, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, 1071 Anyangcheon‑ro, Yangcheon‑gu, Seoul, 07985, Republic of Korea.

Breast cancer occurs at a younger age compared to western countries in South Korea. Despite advancements in treatment methods such as targeted therapy and immunotherapy, the increasing number of patients underscores the importance of improving disease-free survival (DFS). In this study, we evaluated the associations between gut microbiota composition, inflammatory cytokine levels, and breast cancer recurrence in preoperative patients.

View Article and Find Full Text PDF

Osteomyelitis in complicated bones: the role of FDG PET/CT.

Q J Nucl Med Mol Imaging

March 2025

Nuclear Medicine Research Infrastructure (NuMeRI), University of Pretoria and Steve Biko Academic Hospital, Pretoria, South Africa -

Osteomyelitis in infections encompasses heterogeneous group of condition that frequently have high morbidity and comes at a huge cost to healthcare system. Accurate and early diagnosis is important for the proper management of the condition. FDG PET/CT has been found useful in the osteomyelitis of complicated bones, including prosthetic joint infections, fracture related infections and sternal wound infections.

View Article and Find Full Text PDF

Targeted imaging of pulmonary fibrosis by a cyclic peptide LyP-1.

Sci Rep

March 2025

School of Basic Medical Science, Medical Science Research Center, Zhongnan Hospital, Wuhan University, Wuhan, China.

Pulmonary fibrosis (PF) is an interstitial chronic lung disease characterized by interstitial inflammation and extracellular matrix deposition, resulting in progressive lung dysfunction and ultimate respiratory failure. However, lacking of precise and noninvasive tracers for fibrotic lesions limits timely diagnosis and treatment. Here, we identified LyP-1, a cyclic peptide, as a specific and sensitive tracer for PF detection using PET/CT imaging.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!